Gelesis, Inc.   Report issue

For profit
Founded: Boston MA United States (2006)

Organization Overview

First Clinical Trial
2015
NCT02524821
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Gelesis, Inc.

Active Ingredients

Drugs in Other Trials (2)

gelesis100 (1 trial)

sitagliptin (januvia) (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 1
  • # of Trial APIs: 2